Laboratorios Farmaceuticos Rovi, S.A. (LABFF)
USD 90.61
(0.0%)
USD 90.61
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 799.88 Million EUR | -8.97% |
| 2022 | 878.7 Million EUR | 19.93% |
| 2021 | 732.67 Million EUR | 27.55% |
| 2020 | 574.43 Million EUR | 12.37% |
| 2019 | 511.21 Million EUR | 26.95% |
| 2018 | 402.7 Million EUR | 34.96% |
| 2017 | 298.38 Million EUR | 3.66% |
| 2016 | 287.84 Million EUR | 9.1% |
| 2015 | 263.84 Million EUR | 0.97% |
| 2014 | 261.32 Million EUR | 10.76% |
| 2013 | 235.92 Million EUR | 6.1% |
| 2012 | 222.36 Million EUR | -2.5% |
| 2011 | 228.06 Million EUR | 7.13% |
| 2010 | 212.88 Million EUR | 28.31% |
| 2009 | 165.91 Million EUR | 22.08% |
| 2008 | 135.9 Million EUR | 21.17% |
| 2007 | 112.15 Million EUR | 47.5% |
| 2006 | 76.03 Million EUR | -100.0% |
| 2005 | 8150.85 Billion EUR | 103335.75% |
| 2004 | 7.88 Billion EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 778.66 Million EUR | -2.65% |
| 2024 Q2 | 857.32 Million EUR | 10.1% |
| 2023 Q4 | 799.88 Million EUR | -3.71% |
| 2023 FY | 799.88 Million EUR | -8.97% |
| 2023 Q1 | 885.19 Million EUR | 0.74% |
| 2023 Q2 | 899.83 Million EUR | 1.65% |
| 2023 Q3 | 830.72 Million EUR | -7.68% |
| 2022 Q1 | 744.85 Million EUR | 1.66% |
| 2022 FY | 878.7 Million EUR | 19.93% |
| 2022 Q2 | 791.56 Million EUR | 6.27% |
| 2022 Q4 | 878.7 Million EUR | 13.75% |
| 2022 Q3 | 772.46 Million EUR | -2.41% |
| 2021 Q1 | 591.38 Million EUR | 2.95% |
| 2021 Q4 | 732.67 Million EUR | 6.95% |
| 2021 FY | 732.67 Million EUR | 27.55% |
| 2021 Q2 | 644.24 Million EUR | 8.94% |
| 2021 Q3 | 685.06 Million EUR | 6.34% |
| 2020 FY | 574.43 Million EUR | 12.37% |
| 2020 Q4 | 574.43 Million EUR | 2.27% |
| 2020 Q3 | 561.71 Million EUR | 3.29% |
| 2020 Q2 | 543.83 Million EUR | 3.26% |
| 2020 Q1 | 526.66 Million EUR | 3.02% |
| 2019 Q4 | 511.21 Million EUR | 13.06% |
| 2019 Q1 | 427.66 Million EUR | 6.2% |
| 2019 FY | 511.21 Million EUR | 26.95% |
| 2019 Q2 | 449.12 Million EUR | 5.02% |
| 2019 Q3 | 452.17 Million EUR | 0.68% |
| 2018 FY | 402.7 Million EUR | 34.96% |
| 2018 Q3 | 316.15 Million EUR | 1.25% |
| 2018 Q2 | 312.24 Million EUR | 1.6% |
| 2018 Q1 | 307.31 Million EUR | 3.0% |
| 2018 Q4 | 402.7 Million EUR | 27.37% |
| 2017 Q4 | 298.38 Million EUR | 3.02% |
| 2017 FY | 298.38 Million EUR | 3.66% |
| 2017 Q3 | 289.62 Million EUR | -4.42% |
| 2017 Q2 | 303 Million EUR | 0.35% |
| 2017 Q1 | 301.94 Million EUR | 4.9% |
| 2016 Q1 | 265.4 Million EUR | 0.59% |
| 2016 Q2 | 278.59 Million EUR | 4.97% |
| 2016 Q3 | 271.32 Million EUR | -2.61% |
| 2016 Q4 | 287.84 Million EUR | 6.09% |
| 2016 FY | 287.84 Million EUR | 9.1% |
| 2015 Q4 | 263.84 Million EUR | 0.67% |
| 2015 Q2 | 264.59 Million EUR | 1.04% |
| 2015 Q3 | 262.08 Million EUR | -0.95% |
| 2015 Q1 | 261.88 Million EUR | 0.21% |
| 2015 FY | 263.84 Million EUR | 0.97% |
| 2014 Q3 | 245.32 Million EUR | -0.93% |
| 2014 Q2 | 247.64 Million EUR | 4.67% |
| 2014 Q4 | 261.32 Million EUR | 6.52% |
| 2014 FY | 261.32 Million EUR | 10.76% |
| 2014 Q1 | 236.59 Million EUR | 0.28% |
| 2013 Q4 | 235.92 Million EUR | -0.07% |
| 2013 Q3 | 236.08 Million EUR | 2.93% |
| 2013 Q2 | 229.37 Million EUR | 1.95% |
| 2013 Q1 | 224.99 Million EUR | 1.18% |
| 2013 FY | 235.92 Million EUR | 6.1% |
| 2012 Q1 | 219.26 Million EUR | -3.86% |
| 2012 Q4 | 222.36 Million EUR | 2.51% |
| 2012 Q3 | 216.92 Million EUR | -1.07% |
| 2012 FY | 222.36 Million EUR | -2.5% |
| 2012 Q2 | 219.26 Million EUR | 0.0% |
| 2011 Q3 | 218.3 Million EUR | 0.18% |
| 2011 FY | 228.06 Million EUR | 7.13% |
| 2011 Q4 | 228.06 Million EUR | 4.47% |
| 2011 Q2 | 217.91 Million EUR | 0.65% |
| 2011 Q1 | 216.51 Million EUR | 1.7% |
| 2010 FY | 212.88 Million EUR | 28.31% |
| 2010 Q4 | 212.88 Million EUR | 0.0% |
| 2009 FY | 165.91 Million EUR | 22.08% |
| 2008 FY | 135.9 Million EUR | 21.17% |
| 2007 FY | 112.15 Million EUR | 47.5% |
| 2006 FY | 76.03 Million EUR | -100.0% |
| 2005 FY | 8150.85 Billion EUR | 103335.75% |
| 2004 FY | 7.88 Billion EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -1959.062% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -10979.091% |
| SQZ Biotechnologies Company | 107.18 Million USD | -646.251% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -7478.965% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -514.3% |
| Mesoblast Limited | 667.9 Million USD | -19.761% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -1105246.507% |
| Genus plc | 1.02 Billion USD | 22.258% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -58786.313% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -160184.868% |
| Marizyme, Inc. | 22.01 Million USD | -3533.347% |
| ContraFect Corporation | 20.67 Million USD | -3768.098% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -127473.206% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -204806.165% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -209196.739% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -55756.573% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -19192.806% |
| MultiCell Technologies, Inc. | 126.22 USD | -633721972.572% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -85022.205% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -522.429% |
| EV Biologics, Inc. | 431.71 Thousand USD | -185180.996% |
| Q BioMed Inc. | 3.51 Million USD | -22652.955% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -2173.754% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -103694.229% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -306044.054% |
| Biomind Labs Inc. | 73.81 Thousand USD | -1083474.689% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | -72.816% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -2564.952% |
| Skye Bioscience, Inc. | 11.94 Million USD | -6598.965% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -24043.71% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -29025.507% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -40748.151% |
| IMV Inc. | 31.33 Million USD | -2452.784% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -116249.133% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -30626.999% |
| GB Sciences, Inc. | 103.44 Thousand USD | -773168.112% |
| Alpha Cognition Inc. | 2.45 Million USD | -32519.435% |
| HST Global, Inc. | 1526.00 USD | -52416938.008% |
| CSL Limited | 38.02 Billion USD | 97.896% |
| Halberd Corporation | 10.13 Thousand USD | -7895310.127% |
| Enzolytics Inc. | 361.7 Million USD | -121.142% |
| Resverlogix Corp. | 8.11 Million USD | -9756.858% |
| Affymax, Inc. | 7.44 Million USD | -10646.796% |
| SYBLEU INC | 330.46 Thousand USD | -241945.826% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -42495.054% |
| argenx SE | 4.54 Billion USD | 82.391% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -2762.453% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -1576.835% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -3511089.149% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -8838.095% |
| AVAX Technologies, Inc. | 7.37 Million USD | -10742.714% |
| Zenith Capital Corp. | 7410.00 USD | -10794555.87% |
| Genscript Biotech Corporation | 3.38 Billion USD | 76.379% |
| Ember Therapeutics, Inc. | 184.00 USD | -434719465.217% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -248460.934% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -305942.148% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | -79.222% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -55108.466% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | -26341.695% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -1417.778% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -86098.019% |
| BioStem Technologies, Inc. | 14.56 Million USD | -5393.599% |
| ONE Bio Corp. | 70.08 Million USD | -1041.297% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -1400894.851% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -34626912.987% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -80862.623% |
| Agentix Corp. | 261.39 Thousand USD | -305909.365% |
| LadRx Corporation | 2.3 Million USD | -34558.791% |
| Cell Source, Inc. | 195.17 Thousand USD | -409737.527% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -166349.349% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -226100.663% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -226100.663% |
| NovAccess Global Inc. | 62.24 Thousand USD | -1284895.502% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -124949.089% |
| Itoco Inc. | 1.4 Million USD | -57031.633% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -836100.174% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -754507.547% |
| Kadimastem Ltd | 2.3 Million USD | -34615.982% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -1047499.34% |
| CytoDyn Inc. | 11.13 Million USD | -7082.866% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -559368.987% |
| Mobile Lads Corp. | 52.00 USD | -1538238361.538% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -4473524.161% |
| Qrons Inc. | 420.00 USD | -190448471.429% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -207408.217% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -144775.027% |
| Rebus Holdings, Inc. | 5000.00 USD | -15997580.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -195269.081% |
| International Stem Cell Corporation | 5.39 Million USD | -14740.148% |
| Bioxytran, Inc. | 137.63 Thousand USD | -581050.554% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -5231.91% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -4724.682% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -1012411.392% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -92406.682% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -10541.0% |
| Neutra Corp. | 2851.00 USD | -28056160.961% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -2368.321% |
| PureTech Health plc | 693.97 Million USD | -15.262% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -9810.484% |
| IXICO plc | 15.84 Million USD | -4948.529% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -9558.102% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -674.151% |
| CSL Limited | 38.02 Billion USD | 97.896% |
| Cellectis S.A. | 333.99 Million USD | -139.49% |